Intratumoral checkpoint subversion as a strategy for minimizing adverse effects

Citation: Alabanza L, Gnjatic S, Bhardwaj N, Brody J. Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. OncoImmunology 2014; 3:e27580; 10.4161/onci.27580

[1]  A. Weinberg,et al.  OX40-Mediated Memory T Cell Generation Is TNF Receptor-Associated Factor 2 Dependent 1 , 2003, The Journal of Immunology.

[2]  C. Goodnow,et al.  CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10–driven MARCH1-mediated ubiquitination and degradation , 2011, The Journal of experimental medicine.

[3]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[4]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[5]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[6]  D. Moss,et al.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.

[7]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[8]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[9]  Wenda Gao,et al.  OX40 costimulation turns off Foxp3+ Tregs. , 2007, Blood.

[10]  Y. Liu,et al.  Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. , 2007, Cancer research.

[11]  S. Sad,et al.  Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help1 , 2000, The Journal of Immunology.

[12]  C. Slingluff,et al.  The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides , 2012, Journal of immunotherapy.

[13]  L. Zitvogel,et al.  CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? , 2008, Clinical Cancer Research.

[14]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[15]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[16]  H. Schneider,et al.  CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death , 2008, PloS one.

[17]  C. Melief,et al.  Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects , 2013, Clinical Cancer Research.

[18]  J. Yates,et al.  Differential expression of CTLA‐4 among T cell subsets , 2004, Clinical and experimental immunology.

[19]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[20]  P. Sabbatini,et al.  Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients , 2012, Clinical Cancer Research.

[21]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.